View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088
  • 2 Magyar Tudományos Akadémia Molekuláris Medicina Kutatócsoport Budapest
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

A nemszteroid gyulladáscsökkentők (NSAID) a leggyakrabban alkalmazott gyógyszerek közé tartoznak világszerte. Az NSAID-ok súlyos emésztőszervi mellékhatásokat okozhatnak, a szerek a tápcsatorna bármely szakaszát károsíthatják. A ciklooxigenáz-2- (COX-2-) gátlók (coxibok) kifejlesztésétől változatlan gyulladáscsökkentő hatás mellett kedvezőbb emésztőszervi tulajdonságokat vártak. Számos tanulmány igazolta, hogy a coxibok alkalmazása csökkenti a gastroduodenalis fekélybetegség és a fekélyeredetű szövődmények gyakoriságát a hagyományos szerekkel összehasonlítva. Kevesebb adat ismert a coxibok vékony- és vastagbelet érintő mellékhatásairól. A COX-2 konstitutívan expresszálódik a tápcsatornában, és fontos szerepet játszik a bél integritásában. Mind több adat igazolja, hogy a coxibok növelik a szív- és érrendszeri szövődmények gyakoriságát. Az összefoglaló a coxibok biztonságosságával kapcsolatos újabb eredményeket tekinti át.

  • Matuk, R., Crawford, J., Abreu, M. T. és mtsai: The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm. Bowel Dis., 2004, 10 , 352–356.

    Abreu M. T. , 'The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease ' (2004 ) 10 Inflamm. Bowel Dis. : 352 -356.

    • Search Google Scholar
  • Rostom, A., Dubé, C., Lewin, G. és mtsai: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U. S. Preventive Services Task Force. Ann. Intern. Med., 2007, 146 , 376–389.

    Lewin G. , 'Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U. S. Preventive Services Task Force ' (2007 ) 146 Ann. Intern. Med. : 376 -389.

    • Search Google Scholar
  • Psaty, B. M., Furberg, C. D.: COX-2 inhibitors – lessons in drug safety. N. Engl. J. Med., 2005, 352 , 1133–1135.

    Furberg C. D. , 'COX-2 inhibitors – lessons in drug safety ' (2005 ) 352 N. Engl. J. Med. : 1133 -1135.

    • Search Google Scholar
  • Hennan, J. K., Huang, J., Barrett, T. D. és mtsai: Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation, 2001, 104 , 820–825.

    Barrett T. D. , 'Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries ' (2001 ) 104 Circulation : 820 -825.

    • Search Google Scholar
  • Topol, E. J.: Failing the public health-rofecoxib, Merck, and the FDA. N. Engl. J. Med., 2004, 351 , 1707–1709.

    Topol E. J. , 'Failing the public health-rofecoxib, Merck, and the FDA ' (2004 ) 351 N. Engl. J. Med. : 1707 -1709.

    • Search Google Scholar
  • Juni, P., Nartey, L., Reichenbach, S. és mtsai: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet, 2004, 364 , 2021–2029.

    Reichenbach S. , 'Risk of cardiovascular events and rofecoxib: cumulative meta-analysis ' (2004 ) 364 Lancet : 2021 -2029.

    • Search Google Scholar
  • Lazzaroni, M., Battocchia, A., Porro, G. B.: COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do? Dig. Liv. Dis., 2007, 39 , 589–596.

    Porro G. B. , 'COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do? ' (2007 ) 39 Dig. Liv. Dis. : 589 -596.

    • Search Google Scholar
  • Vane, J. R.: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like grugs. Nat. New Biol., 1971, 231 , 232–235.

    Vane J. R. , 'Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like grugs ' (1971 ) 231 Nat. New Biol. : 232 -235.

    • Search Google Scholar
  • Vane, J. R., Botting, R. M.: Mechanism of action of non-steroidal antiinflammatory drugs. Am. J. Med., 1998, 104 , 2–8.

    Botting R. M. , 'Mechanism of action of non-steroidal antiinflammatory drugs ' (1998 ) 104 Am. J. Med. : 2 -8.

    • Search Google Scholar
  • Warner, T. D., Mitchell, J. A.: Cyclooxygenases: new forms, new inhibitors, and lessons for the clinic. FASEB J., 2004, 18 , 790–804.

    Mitchell J. A. , 'Cyclooxygenases: new forms, new inhibitors, and lessons for the clinic ' (2004 ) 18 FASEB J. : 790 -804.

    • Search Google Scholar
  • Lanas, A., Perez-Aisa, M. A., Feu, F. és mtsai: A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non-steroidal anti-inflammatory drug use. Am. J. Gastroenterol., 2005, 100 , 1685–1693.

    Feu F. , 'A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non-steroidal anti-inflammatory drug use ' (2005 ) 100 Am. J. Gastroenterol. : 1685 -1693.

    • Search Google Scholar
  • Wolfe, M. M., Lichtenstein, D. R., Singh, G.: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drug. N. Engl. J. Med., 1999, 340 , 1888–1899.

    Singh G. , 'Gastrointestinal toxicity of nonsteroidal anti-inflammatory drug ' (1999 ) 340 N. Engl. J. Med. : 1888 -1899.

    • Search Google Scholar
  • Allison, M. C., Howatson, A. G., Torrance, C. J. és mtsai: Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. N. Engl. J. Med., 1992, 327 , 49–54.

    Torrance C. J. , 'Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs ' (1992 ) 327 N. Engl. J. Med. : 49 -54.

    • Search Google Scholar
  • Kessler, W. F., Shires, G. T., Fahey, T. J.: Surgical complications of non-steroidal antiinflammatory drug-induced small bowel ulceration. J. Am. Coll. Surg., 1997, 185 , 250–254.

    Fahey T. J. , 'Surgical complications of non-steroidal antiinflammatory drug-induced small bowel ulceration ' (1997 ) 185 J. Am. Coll. Surg. : 250 -254.

    • Search Google Scholar
  • Morris, A. J., Madhok, R., Sturrock, R. D. és mtsai: Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal antiinflammatory drugs. Lancet, 1991, 337 , 520.

    Sturrock R. D. , 'Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal antiinflammatory drugs ' (1991 ) 337 Lancet : 520 -.

    • Search Google Scholar
  • Maiden, L., Thjodleifsson, B., Theodors, A. és mtsai: A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology, 2005, 128 , 1172–1178.

    Theodors A. , 'A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy ' (2005 ) 128 Gastroenterology : 1172 -1178.

    • Search Google Scholar
  • Etienney, I., Beaugerie, L., Viboud, C. és mtsa: Non-steroidal antiinflammatory drugs as a risk factor for acute diarrhoea: a case crossover study. Gut, 2003, 52 , 260–263.

    Viboud C. , 'Non-steroidal antiinflammatory drugs as a risk factor for acute diarrhoea: a case crossover study ' (2003 ) 52 Gut : 260 -263.

    • Search Google Scholar
  • Tanner, A. R., Raghunath, A. S.: Colonic inflammation and nonsteroidal anti-inflammatory drug administration: an assessment of the frequency of the problem. Digestion, 1988, 41 , 116–120.

    Raghunath A. S. , 'Colonic inflammation and nonsteroidal anti-inflammatory drug administration: an assessment of the frequency of the problem ' (1988 ) 41 Digestion : 116 -120.

    • Search Google Scholar
  • Pan, Y. S., Chen, L. T., Tseng, C. A. és mtsai: Clinical and endoscopic features of non-steroidal anti-inflammatory drug-induced colorectal ulcerations. J. Formos. Med. Assoc., 2005, 104 , 804–810.

    Tseng C. A. , 'Clinical and endoscopic features of non-steroidal anti-inflammatory drug-induced colorectal ulcerations ' (2005 ) 104 J. Formos. Med. Assoc. : 804 -810.

    • Search Google Scholar
  • Rubinstein, J. H., Laine, L.: Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Ther., 2004, 20 , 373–380.

    Laine L. , 'Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs ' (2004 ) 20 Aliment. Pharmacol. Ther. : 373 -380.

    • Search Google Scholar
  • Hawkey, C. J.: Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology, 2000, 119 , 521–535.

    Hawkey C. J. , 'Nonsteroidal anti-inflammatory drug gastropathy ' (2000 ) 119 Gastroenterology : 521 -535.

    • Search Google Scholar
  • Bjarnason, I., Smethurst, P., Price, A. és mtsa: Metronidazole reduces intestinal inflammation and blood loss in NSAID-induced enteropathy. Gut, 1992, 33 , 1204–1208.

    Price A. , 'Metronidazole reduces intestinal inflammation and blood loss in NSAID-induced enteropathy ' (1992 ) 33 Gut : 1204 -1208.

    • Search Google Scholar
  • Silverstein, F. E., Faich, G., Goldstein, J. L. és mtsai: Gastrointestinal toxicity with celecoxib vs. nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis (the CLASS study): a randomized controlled trial. J. Am. Med. Assoc., 2000, 284 , 1247–1255.

    Goldstein J. L. , 'Gastrointestinal toxicity with celecoxib vs. nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis (the CLASS study): a randomized controlled trial ' (2000 ) 284 J. Am. Med. Assoc. : 1247 -1255.

    • Search Google Scholar
  • Bombardier, C., Laine, L., Reicin, A. és mtsai: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med., 2000, 343 , 1520–1528.

    Reicin A. , 'Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis ' (2000 ) 343 N. Engl. J. Med. : 1520 -1528.

    • Search Google Scholar
  • Eisen, G. M., Goldstein, J. L., Hanna, D. B. és mtsa: Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Aliment. Pharmacol. Ther., 2005, 21 , 591–598.

    Hanna D. B. , 'Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis ' (2005 ) 21 Aliment. Pharmacol. Ther. : 591 -598.

    • Search Google Scholar
  • Rostom, A., Muir, K., Dubé, C. és mtsai: Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane-collaboration systematic review. Clin. Gast. Hepatol., 2007, 5 , 818–828.

    Dubé C. , 'Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane-collaboration systematic review ' (2007 ) 5 Clin. Gast. Hepatol. : 818 -828.

    • Search Google Scholar
  • Hawkey, C. J., Laine, L., Simon, T. és mtsai: Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut, 2003, 52 , 820–826.

    Simon T. , 'Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study ' (2003 ) 52 Gut : 820 -826.

    • Search Google Scholar
  • Mamdani, M., Juurlink, D. N., Kopp, A. és mtsai: Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. Br. Med. J., 2004, 328 , 1415–1416.

    Kopp A. , 'Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study ' (2004 ) 328 Br. Med. J. : 1415 -1416.

    • Search Google Scholar
  • Lanas, A., Baron, J. A., Sandler, R. S. és mtsai: Peptic Ulcer and Bleeding Events Associated with Rofecoxib in a 3-Year Colorectal Adenoma Chemoprevention Trial. Gastroenterology, 2007, 132 , 490–497.

    Sandler R. S. , 'Peptic Ulcer and Bleeding Events Associated with Rofecoxib in a 3-Year Colorectal Adenoma Chemoprevention Trial ' (2007 ) 132 Gastroenterology : 490 -497.

    • Search Google Scholar
  • Laine, L., Maller, E. S., Yu, C. és mtsai: Ulcer Formation with Low-Dose Enteric-Coated Aspirin and the Effect of COX-2 Selective Inhibition: A Double-Blind Trial. Gastroenterology, 2004, 127 , 395–402.

    Yu C. , 'Ulcer Formation with Low-Dose Enteric-Coated Aspirin and the Effect of COX-2 Selective Inhibition: A Double-Blind Trial ' (2004 ) 127 Gastroenterology : 395 -402.

    • Search Google Scholar
  • Schnitzer, T. J., Burmester, G. R., Mysler, E. és mtsai: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial [TARGET), reduction in ulcer complications: randomised controlled trial. Lancet, 2004, 364 , 665–674.

    Mysler E. , 'Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial [TARGET), reduction in ulcer complications: randomised controlled trial ' (2004 ) 364 Lancet : 665 -674.

    • Search Google Scholar
  • Rostom, A., Dube, C., Wells, G. és mtsai: Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database. Syst. Rev., 2002, CD002296.

  • Chan, F. K., Hung, L. C., Suen, B. Y. és mtsai: Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology, 2004, 127 , 1038–1043.

    Suen B. Y. , 'Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial ' (2004 ) 127 Gastroenterology : 1038 -1043.

    • Search Google Scholar
  • Chan, F. K., Wong, V. W., Suen, B. Y. és mtsai: Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet, 2007, 369 , 1621–1626.

    Suen B. Y. , 'Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial ' (2007 ) 369 Lancet : 1621 -1626.

    • Search Google Scholar
  • Spiegel, B., Farid, M., Dulai, G. S. és mtsai: Comparing rates of dyspepsia with coxibs vs. NSAID_PPI: A meta-analysis. Am. J. Med., 2006, 119 , 27–36.

    Dulai G. S. , 'Comparing rates of dyspepsia with coxibs vs. NSAID_PPI: A meta-analysis ' (2006 ) 119 Am. J. Med. : 27 -36.

    • Search Google Scholar
  • Graham, D. Y., Agrawal, N. M., Campbell, D. R. és mtsai: Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprazole. Arch. Intern. Med., 2002, 162 , 169–175.

    Campbell D. R. , 'Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprazole ' (2002 ) 162 Arch. Intern. Med. : 169 -175.

    • Search Google Scholar
  • Bjarnason, I., Zanelli, G., Prouse, P. és mtsai: Blood and protein loss via small intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet, 1987, 2 , 711–714.

    Prouse P. , 'Blood and protein loss via small intestinal inflammation induced by non-steroidal anti-inflammatory drugs ' (1987 ) 2 Lancet : 711 -714.

    • Search Google Scholar
  • Sightorsson, G., Simpson, R. J., Walley, M. és mtsai: COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology, 2002, 122 , 1913–1923.

    Walley M. , 'COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice ' (2002 ) 122 Gastroenterology : 1913 -1923.

    • Search Google Scholar
  • Newberry, R. D., McDonough, J. S., Stenson, W. F. és mtsa: Spontaneous and continuous cyclooxygenase-2-dependent prostaglandin E2 production by stromal cells in the murine small intestine lamina propria: directing the tone of the intestinal immune response. J. Immunology, 2001, 166 , 4465–4472.

    Stenson W. F. , 'Spontaneous and continuous cyclooxygenase-2-dependent prostaglandin E2 production by stromal cells in the murine small intestine lamina propria: directing the tone of the intestinal immune response ' (2001 ) 166 J. Immunology : 4465 -4472.

    • Search Google Scholar
  • Laine, L., Connors, L. G., Reicin, A. és mtsai: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology, 2003, 124 , 288–292.

    Reicin A. , 'Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use ' (2003 ) 124 Gastroenterology : 288 -292.

    • Search Google Scholar
  • Goldstein, J. L., Eisen, G. M., Lewis, B. és mtsai: Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment. Pharmacol. Ther., 2007, 25 , 1211–1222.

    Lewis B. , 'Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy ' (2007 ) 25 Aliment. Pharmacol. Ther. : 1211 -1222.

    • Search Google Scholar
  • Thiéfin, G., Beaugerie, L.: Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine, 2005, 72 , 286–294.

    Beaugerie L. , 'Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum ' (2005 ) 72 Joint Bone Spine : 286 -294.

    • Search Google Scholar
  • Morris, C. R., Harvey, I. M., Stebbings, W. S. L. és mtsai: Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease. Br. J. Surg., 2003, 90 , 1267–1272.

    Stebbings W. S. L. , 'Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease ' (2003 ) 90 Br. J. Surg. : 1267 -1272.

    • Search Google Scholar
  • Reinisch, W., Miehsler, W. P., Dejaco, C.: Treatment of peripheral arthropathy in IBD with rofecoxib, a selective COX-2 inhibitor. Gastroenterology, 2002, 118 , A277.

    Dejaco C. , 'Treatment of peripheral arthropathy in IBD with rofecoxib, a selective COX-2 inhibitor ' (2002 ) 118 Gastroenterology : A277 -.

    • Search Google Scholar
  • Biancone, L., Tosti, C., De Nigris, F. és mtsai: Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease. Gastroenterology, 2003, 125 , 637–638.

    Nigris F. , 'Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease ' (2003 ) 125 Gastroenterology : 637 -638.

    • Search Google Scholar
  • Bresalier, R. S., Sandler, R. S., Quan, H. és mtsai: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 2005, 352 , 1092–1102.

    Quan H. , 'Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial ' (2005 ) 352 N. Engl. J. Med. : 1092 -1102.

    • Search Google Scholar
  • Maxwell, S. R., Webb, D. J.: COX-2 selective inhibitors – important lessons learned. Lancet, 2005, 365 , 449–451.

    Webb D. J. , 'COX-2 selective inhibitors – important lessons learned ' (2005 ) 365 Lancet : 449 -451.

    • Search Google Scholar
  • McGettigan, P., Henry, D.: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA, 2006, 296 , 1633–44.

    Henry D. , 'Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2 ' (2006 ) 296 JAMA : 1633 -44.

    • Search Google Scholar
  • Solomon, S. D., McMurray, J. J., Pfeffer, M. A. és mtsai: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med., 2005, 352 , 1071–1080.

    Pfeffer M. A. , 'Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention ' (2005 ) 352 N. Engl. J. Med. : 1071 -1080.

    • Search Google Scholar
  • Pfizer: A double blind, randomized, placebo-controlled, comparative study of celecoxib [SC-58635] for the inhibition of progression of Alzheimer’s disease. http://www.clinicalstudyresults.org/documents/company-study_76_0.pdf

  • White, W. B., Strand, V., Roberts, R. és mtsa: Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus non-steroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am. J. Ther., 2004, 11 , 244–250.

    Roberts R. , 'Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus non-steroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis ' (2004 ) 11 Am. J. Ther. : 244 -250.

    • Search Google Scholar
  • Farkouh, M. E., Kirshner, H., Harrington, R. A. és mtsai: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial [TARGET], cardiovascular outcomes: randomised controlled trial. Lancet, 2004, 364 , 675–684.

    Harrington R. A. , 'Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial [TARGET], cardiovascular outcomes: randomised controlled trial ' (2004 ) 364 Lancet : 675 -684.

    • Search Google Scholar
  • EMEA, 2005: http://www.emea.europa.eu/pdfs/human/ press/pr/6275705en.pdf

  • FDA, 2005: http://www.fda.gov/cder/drug/infopage/ COX2/default.htm

  • Kearney, P. M., Baigent, C., Godwin, J. és mtsai: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 2006, 332 , 1302–1308.

    Godwin J. , 'Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials ' (2006 ) 332 BMJ : 1302 -1308.

    • Search Google Scholar